Want to see HIMS full AI Analyst Report?
Top Page
Hims & Hers Health
(NYSE:HIMS)
Select Model
Select Model
Rating:54Neutral
Price Target:
$34.00
▲(13.98% Upside)
Action:Reiterated
Date:08/11/26
The score is driven primarily by uneven financial performance—excellent top-line growth and positive TTM cash generation, but pressured by sharply higher leverage, margin compression, and a return to TTM losses. The latest earnings call supports the outlook via raised guidance and scaling subscriber/international growth, while technicals are broadly neutral and valuation remains weak due to negative earnings and no dividend support.
Positive Factors
Strong revenue and subscriber growth
Rapid revenue and subscriber expansion indicates strong customer adoption and increasing platform scale. A larger recurring base can support retention, cross-selling and more efficient customer acquisition over the next several quarters.
Negative Factors
High and rising leverage
Debt has risen sharply while equity remains modest, reducing financial flexibility and increasing obligations during periods of weaker profitability. Elevated leverage could constrain investment capacity and amplify the impact of margin or cash-flow volatility.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue and subscriber growth
Rapid revenue and subscriber expansion indicates strong customer adoption and increasing platform scale. A larger recurring base can support retention, cross-selling and more efficient customer acquisition over the next several quarters.
Read all positive factors
Hims & Hers Health Key Performance Indicators (KPIs)
Any
Subscriptions
Tracks the number of active subscriptions, highlighting recurring revenue streams and customer retention strength.
Tracks the number of active subscriptions, highlighting recurring revenue streams and customer retention strength.
Data provided by:
The Fly
The FlyHims & Hers Health (HIMS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.41B
Dividend YieldN/A
Average Volume (3M)15.98M
Price to Earnings (P/E)―
Beta (1Y)2.55
Revenue Growth28.04%
EPS Growth-169.91%
CountryUS
Employees2,442
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.61
Shares Outstanding224,935,790
10 Day Avg. Volume14,448,064
30 Day Avg. Volume15,981,831
Financial Highlights & Ratios
PEG Ratio-33.04
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.11Price Target Upside11.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$3.17B
Hims & Hers Health Business Overview & Revenue Model
Company Description
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the comp...
How the Company Makes Money
Hims & Hers primarily makes money through direct-to-consumer sales tied to its telehealth platform and product fulfillment. The core revenue model is built around (1) subscriptions/recurring plans and (2) one-time product sales. Customers typicall...
Hims & Hers Health Earnings Call Summary
Earnings Call Date:Aug 10, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Positive
Overall the call conveyed a constructive and growth-oriented outlook: strong revenue and subscriber growth, raised guidance, meaningful international scale from the Eucalyptus acquisition, and promising AI-driven engagement and efficiency gains. These positives are tempered by margin compression from mix shift toward branded weight loss and international sales, a GAAP loss driven by one-time costs, short-term negative cash flow in the quarter, and regulatory/legal uncertainties (FTC action and dependence on FDA rulemaking for peptides). Management highlighted liquidity actions and expects AI investments to pay back within 12–18 months, signaling confidence in the path to improved profitability.Positive Updates
Strong Top-Line Growth
Revenue grew nearly 40% year-over-year to more than $753 million in Q2 2026, driven by expanded assortment, new geographies and subscriber additions.
Negative Updates
Gross Margin Compression
Adjusted gross margin was 64% in Q2, down approximately 6 percentage points quarter-over-quarter, driven by deliberate mix shift toward lower-margin branded weight loss products and growing international revenue.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Top-Line Growth
Revenue grew nearly 40% year-over-year to more than $753 million in Q2 2026, driven by expanded assortment, new geographies and subscriber additions.
Read all positive updates
Company Guidance
Management raised short‑term guidance and framed a growth + investment cadence: Q3 revenue is guided to $880–900M (+47–50% YoY) with adjusted EBITDA $75–95M (≈10% margin at midpoint), and full‑year 2026 revenue is now $3.1–3.3B (+32–41% YoY) with adjusted EBITDA $275–325M (≈9% margin at midpoint). They noted Q2 results of >$753M revenue (+~40% YoY) — $622M domestic (+16% YoY) and $131M international (>17x YoY, with Eucalyptus contributing ~ $40M) — adjusted EBITDA $60M (8% margin), GAAP net loss $86M, gross margin 64% (≈‑6 pts QoQ), operating cash flow of ‑$36M and free cash flow of ‑$68M in Q2 (>$260M operating cash flow over the last 12 months). Balance‑sheet actions include a $400M receivables facility, >$400M of convertible debt, >$840M cash & short‑term investments after a ~$225M upfront Eucalyptus payment, and $225M remaining on the buyback; international revenue is expected to be ≥$600M in 2026. Other measurable milestones cited: ~300k net new subscribers in Q2 (nearly 3M total), Hers on track for >$1B this year, five U.S. specialties >$100M annual run‑rate with testosterone becoming a sixth, U.K./Australia/Germany each >$100M annualized, AI pilot results showing 3x messaging, AI answering 80% of queries and ~50% reduction in nonclinical support tasks, and AI investments expected to pay back in 12–18 months, all underpinning the 2030 targets of ≥$6.5B revenue and $1.3B adjusted EBITDA.Hims & Hers Health Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
34
Negative
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.58B | 2.35B | 1.48B | 872.00M | 526.92M | 271.88M |
| Gross Profit | 1.67B | 1.73B | 1.17B | 714.95M | 408.72M | 204.49M |
| EBITDA | -76.42M | 178.43M | 88.80M | -12.06M | -58.23M | -106.72M |
| Net Income | -142.03M | 128.37M | 126.04M | -23.55M | -65.68M | -107.66M |
Balance Sheet | ||||||
| Total Assets | 3.63B | 2.15B | 707.54M | 441.19M | 366.34M | 420.58M |
| Cash, Cash Equivalents and Short-Term Investments | 841.05M | 577.49M | 300.25M | 220.98M | 179.63M | 247.27M |
| Total Debt | 1.55B | 1.12B | 11.35M | 9.95M | 5.31M | 5.48M |
| Total Liabilities | 3.30B | 1.61B | 230.82M | 97.16M | 54.60M | 85.97M |
| Stockholders Equity | 324.07M | 540.93M | 476.72M | 344.03M | 311.74M | 334.62M |
Cash Flow | ||||||
| Free Cash Flow | 89.89M | 73.96M | 198.33M | 46.99M | -33.78M | -39.42M |
| Operating Cash Flow | 266.84M | 300.01M | 251.08M | 73.48M | -26.53M | -34.41M |
| Investing Cash Flow | -901.98M | -1.02B | -19.05M | -12.11M | 34.70M | -156.27M |
| Financing Cash Flow | 123.95M | 729.62M | -107.84M | -11.47M | -33.13M | 235.04M |
Hims & Hers Health Technical Analysis
Negative
29.83
Price Trends
32.17
Negative
29.01
Positive
28.71
Positive
Market Momentum
-0.07
Negative
47.64
Neutral
49.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIMS, the sentiment is Negative. The current price of 29.83 is below the 20-day moving average (MA) of 30.26, below the 50-day MA of 32.17, and above the 200-day MA of 28.71, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 47.64 is Neutral, neither overbought nor oversold. The STOCH value of 49.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HIMS.
Hims & Hers Health Risk Analysis
Hims & Hers Health disclosed 72 risk factors in its most recent earnings report. Hims & Hers Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Hims & Hers Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $4.41B | 27.80 | 16.95% | ― | 11.18% | -28.59% | |
66 Neutral | $1.19B | 69.39 | 2.61% | ― | -1.83% | -48.77% | |
58 Neutral | $1.33B | -14.33 | -6.27% | 2.17% | -7.00% | -246.78% | |
54 Neutral | $7.41B | -48.90 | -30.03% | ― | 28.04% | -169.91% | |
52 Neutral | $1.12B | -6.39 | -13.08% | ― | -2.08% | 16.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $236.08M | -1.09 | -29.42% | 4.72% | -15.44% | -319.79% |
* Healthcare Sector Average
HIMS
Hims & Hers Health
29.83
-14.18
-32.22%
NUS
Nu Skin
4.84
-7.02
-59.17%
TDOC
Teladoc
6.33
-1.41
-18.22%
EPC
Edgewell Personal Care
28.65
5.82
25.49%
GDRX
GoodRx Holdings
3.65
-0.85
-18.89%
DOCS
Doximity
24.74
-43.25
-63.61%
Hims & Hers Health Corporate Events
Executive/Board Changes
Hims & Hers Health Announces Accounting Officer Resignation
Neutral
Jul 17, 2026
Hims Hers Health, Inc. disclosed that Irene Becklund notified the company on July 13, 2026, of her decision to resign as Chief Accounting Officer and Principal Accounting Officer, effective October 9, 2026. The company stated that Becklund’...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Hims & Hers Establishes New $400 Million Receivables Facility
Positive
Jul 1, 2026
On July 1, 2026, XeCare LLC and Apostrophe Pharmacy LLC, subsidiaries of Hims Hers Health, entered a Master Receivables Purchase Agreement with JPMorgan Chase Bank that allows them to sell up to $400 million in eligible receivables at a discount,...
Executive/Board ChangesShareholder Meetings
Hims & Hers Shareholders Reaffirm Board, Pay, and Auditor
Positive
Jun 15, 2026
On June 11, 2026, Hims Hers Health, Inc. held its annual meeting of stockholders, where holders of Class A and high-vote Class V shares, acting as a single class, elected nine directors to serve until the 2027 annual meeting. The director slate, ...
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
Hims & Hers Closes Eucalyptus Deal, Expands Global Platform
Positive
Jun 2, 2026
On May 29, 2026, Hims Hers Health, Inc. amended its Revolving Credit and Guaranty Agreement to facilitate the closing of its acquisition of Australian-based EUC Management Pty Ltd, known as Eucalyptus, while largely preserving existing loan terms...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.